REPLY
22.2.2021 10:02:09 CET | Business Wire | Press release
The pandemic has accelerated the trend of adopting new interfaces in both consumer and professional fields, according to Reply’s new research “New Interfaces, Zero Interfaces” , based on Reply’s Trend SONAR proprietary data-driven platform.
The research explores the development prospects of state-of-the-art interfaces that are coming to prominence in this new normal by analysing significant studies, scientific articles and patents published in the last two years, while integrating them with relevant experiences from Reply customers.
Smartphones and their operating systems have been enabling completely new experiences for almost 15 years; now 5G, high-speed connectivity, and edge computing are set to provide a further boost for user interface technologies like wearables, smart speakers, 3D spatial interfaces, multimodal and brain-computer interfaces.
“Companies will develop more personalized and emotional interactions with customers, as well as new possibilities for the analysis and visualization of information,” commented Filippo Rizzante, CTO Reply. "Looking at the impacts of the pandemic on the interfaces we use today, there are two trends that more than others we are seeing growing: a wider demand for remote healthcare, and the need to reduce touch interfaces".
Voice is the fastest growing interface, thanks to its frequent use in daily life through smart speakers and cars. It is also increasingly being used for marketing purposes, allowing popular brands to literally speak directly to consumers – a much more intimate connection than the ones offered by traditional touchpoints.
Industries like pharmaceuticals, fashion, real estate, and travel are progressively implementing extended reality technologies through mobile apps or special headsets. Extended Reality is set to greatly enhance training and workplace collaboration, offering teams much better ways of meeting and sharing ideas and thoughts in both virtual and augmented realities.
Wearables are becoming steadily more relevant in the field of daily-use interfaces. Rings, glasses, and ‘hearables’ can be connected to smart assistants to help with daily life and monitor behaviour. Combined with next-gen smartwatches, these kind of wearables could become the first full-alternative, independent, consumer-ecosystem to the smartphone.
Gaze control and eye tracking will allow people to control, communicate and interact with machines based on eye movement patterns, fixations and pupil reaction. Brain-computer interface (BCI) technology is accelerating as well. The focus is still predominantly medical and scientific, however its diffusion into other areas is increasing, blurring the lines between computing and biology.
In the mobility industry , new interfaces will have a crucial role in the safety and the security of vehicle drivers and pedestrians, using new smart technologies to improve safety and communications with other road users. New interfaces will also make cars and trucks more customisable and predictive. Moreover, autonomous driving will enable greater development in entertainment and advertising within vehicles.
Retail-related interface development is experiencing seismic shifts as well, helping shoppers enjoy the benefits of physical shopping – tactile, sensory and social – in digital virtual spaces that enable frictionless and comfortable shopping while driving customer acquisition, retention and loyalty to new heights. The use of Artificial Intelligence-based and conversational interfaces will refine customisation down to the needs of the individual customer. AI and digital technologies allow for more personalisation for customers, from inspiration to tackling sizing and fitting issues in fashion retail.
With increasing sensor integration and natural embedding into the surrounding world, interfaces will be invisibly interwoven into everyday life and work environments, turning anything into an interface, seamlessly communicating with each other and expanding human cognition and senses.
For more insights download the full research “New Interfaces, Zero Interfaces” . This new research is part of the Reply Market Research series, including the recent “From Cloud to Edge” and “Rebooting Longevity” .
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
